Structural mimicry of UM171 and neomorphic cancer mutants co-opts E3 ligase KBTBD4 for HDAC1/2 recruitment.
Chen Z. et al, (2025), Nat Commun, 16
Toward target 2035: EUbOPEN - a public-private partnership to enable & unlock biology in the open.
Tredup C. et al, (2024), RSC Med Chem
A BTB extension and ion-binding domain contribute to the pentameric structure and TFAP2A binding of KCTD1.
Pinkas DM. et al, (2024), Structure
Discovery of Two Highly Selective Structurally Orthogonal Chemical Probes for Activin Receptor-like Kinases 1 and 2.
Němec V. et al, (2024), J Med Chem
Discovery and Characterization of a Chemical Probe for Cyclin-Dependent Kinase-Like 2.
Bashore FM. et al, (2024)
BTB domain mutations perturbing KCTD15 oligomerisation cause a distinctive frontonasal dysplasia syndrome.
Miller KA. et al, (2024), J Med Genet, 61, 490 - 501
Still in Search for an EAAT Activator: GT949 Does Not Activate EAAT2, nor EAAT3 in Impedance and Radioligand Uptake Assays.
van Veggel L. et al, (2024), ACS Chem Neurosci, 15, 1424 - 1431
Discovery of Conformationally Constrained ALK2 Inhibitors.
González-Álvarez H. et al, (2024), J Med Chem, 67, 4707 - 4725
Author Correction: CIS is a potent checkpoint in NK cell-mediated tumor immunity.
Delconte RB. et al, (2024), Nat Immunol, 25, 371 - 372
PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo.
Brown EJ. et al, (2024), Sci Rep, 14
Discovery and Characterization of a Chemical Probe for Cyclin-Dependent Kinase-Like 2
Bashore FM. et al, (2024), ACS Medicinal Chemistry Letters
Structural and biochemical characterization establishes a detailed understanding of KEAP1-CUL3 complex assembly.
Adamson RJ. et al, (2023), Free Radic Biol Med, 204, 215 - 225
Target 2035 - an update on private sector contributions.
Ackloo S. et al, (2023), RSC Med Chem, 14, 1002 - 1011
Discovery of a Potent and Selective CDKL5/GSK3 Chemical Probe That Is Neuroprotective.
Ong HW. et al, (2023), ACS Chem Neurosci, 14, 1672 - 1685